Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 6:13:1015959.
doi: 10.3389/fphar.2022.1015959. eCollection 2022.

Editorial: Novel agents and combinations for treatment of malignant pleural mesothelioma in pre-clinical models

Sze-Kwan Lam  1 , Steven Eugene Mutsaers  2
Affiliations
Editorial

Editorial: Novel agents and combinations for treatment of malignant pleural mesothelioma in pre-clinical models

Sze-Kwan Lam et al. Front Pharmacol. .
No abstract available

Keywords: animal models; malignant pleural mesothelioma; novel combinations; novel therapies; review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Novel agents and combinations for treatment of malignant pleural mesothelioma in pre-clinical models

References

    1. Chapel D. B., Dubuc A. M., Hornick J. L., Sholl L. M. (2021). Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma. Histopathology 78 (7), 1032–1042. 10.1111/his.14324 - DOI - PubMed
    1. Cordier F., Van der Meulen J., van Roy N., De Wilde J., van Dijck H., Vanhoenacker F., et al. (2022). Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected. Pathol. Res. Pract. 231, 153772. 10.1016/j.prp.2022.153772 - DOI - PubMed
    1. Fennell D. A., King A., Mohammed S., Greystoke A., Anthony S., Poile C., et al. (2022). Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): A single-arm, open-label, phase 2 trial. Lancet. Oncol. 23 (3), 374–381. 10.1016/S1470-2045(22)00062-6 - DOI - PubMed
    1. Hampton T. (2017). Bench to bedside and back again may Be key to clinical breakthroughs. JAMA 318 (1), 16–17. 10.1001/jama.2017.7276 - DOI - PubMed
    1. Hanahan D., Weinberg R. A. (2000). The hallmarks of cancer. Cell 100 (1), 57–70. 10.1016/s0092-8674(00)81683-9 - DOI - PubMed

Publication types

LinkOut - more resources